Abstract
This paper aims to characterize the main actors in the Brazilian pharmaceutical industry ? national companies, foreign companies and public laboratories ? and analyze how they were affected and how they reacted to changes over the last 30 years in the institutional framework. The results show that national companies have been gaining prominence in the Brazilian pharmaceutical market with their internationalization movement and their strengthening of innovation strategies.
| Original language | English |
|---|---|
| Pages (from-to) | 126-135 |
| Number of pages | 10 |
| Journal | Journal of Law, Medicine & Ethics |
| Volume | 51 |
| Issue number | S1 |
| DOIs | |
| Publication status | Published (VoR) - 29 Dec 2023 |
Funding
The third cycle occurred after Dilma’s impeachment in 2016, with the governments of Michel Temer and Jair Bolsonaro, initiating a phase of institutional instability and new directions of industrial development stimuli (horizontal and implicit policies). This cycle was marked by the absence of explicit and vertical industrial policies, disruption of policy instruments for the pharmaceutical industry and the CIS, and disarticulation of the coordination instances in the MoH. On the STI side, the National Science, Technology and Innovation Strategy was maintained (2016-2022) but suffered a substantial reduction in the available resources for research grants and innovation funds.
Keywords
- Pharmaceutical Industry
- Development policies
- Institutional framework
- Brazil